The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an ...

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in patients with previously untreated, locally advanced head and neck ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head ...

Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...

This part of the Phase II study evaluates eftilagimod alfa (efti) in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first line ...

Anticipates initiating the Company's Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for ...

As of March 31, 2025, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments, of $106.9 million. The Company believes that its current cash, cash ...